• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Dogwood Therapeutics Inc.

    3/17/25 5:49:29 PM ET
    $DWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DWTX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Dogwood Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    92829J203

    (CUSIP Number)


    03/12/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    92829J203


    1Names of Reporting Persons

    Orca Capital AG
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    GERMANY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    115,790.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    115,790.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    115,790.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.1 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  All ownership percentages set forth in this Schedule 13G are calculated based upon an aggregate of 1,911,128 shares of Common Stock outstanding immediately after giving effect to the completion of the Issuer's registered offering as described in the Issuer's Prospectus Supplement filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on March 14, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Dogwood Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    44 Milton Ave, Alpharetta, GA 30009
    Item 2. 
    (a)Name of person filing:

    Orca Capital AG
    (b)Address or principal business office or, if none, residence:

    Sperlring 2 85276 Hettenshausen Deutschland
    (c)Citizenship:

    Germany
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    92829J203
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    115,790 shares of the Issuer's common stock, par value $0.001 per share
    (b)Percent of class:

    6.1  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    115,790

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    115,790

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Orca Capital AG
     
    Signature:/s/ Thomas Konig
    Name/Title:Thomas Konig/Director
    Date:03/17/2025
    Get the next $DWTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DWTX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DWTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference

      ATLANTA, June 03, 2025 (GLOBE NEWSWIRE) --  Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced that CEO, Greg Duncan, will present a corporate overview at the Sidoti Small-Cap Virtual Conference being held on Wednesday, June 11, 2025 – Thursday, June 12, 2025. Presentation Date: Wednesday, June 11, 2025  Time:  9:15am Easter Time (Track 1) Webcast Link: https://sidoti.zoom.us/webinar/register/WN_C6ACWY1kTXGa0eBkFbVd0w Mr. Duncan will be available for one-on-one meetings. To request a meeting and to register for the conference, click here: htt

      6/3/25 9:15:00 AM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dogwood Therapeutics Announces First Quarter 2025 Financial Results

      - Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Study - - Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b study interim data readout is expected in Q4 2025 - - Cash on hand of $17.5M provides operational runway through Q1 2026 - ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced financial results for the first quarter ended March 31, 2025. "There are no FDA approved treatments to manage the neuropathic pain often resulting from

      5/8/25 9:00:00 AM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

      ATLANTA, April 11, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders, today announced that it has received written confirmation from Nasdaq that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders' equity of $2.5 million. DWTX Chairman and CEO Greg Duncan stated, "We are pleased that the Company successfully implemented a plan to regain compliance and meet the equity requirement and is continuing to execute that plan going forward." He continued, "The Company has a strong cash positi

      4/11/25 9:15:00 AM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DWTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Conjoint Inc.

      3 - Dogwood Therapeutics, Inc. (0001818844) (Issuer)

      3/20/25 8:19:58 PM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Ck Life Sciences Intl (Holdings) Inc

      4 - Dogwood Therapeutics, Inc. (0001818844) (Issuer)

      3/17/25 9:07:18 PM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Yu Ying Choi Alan Abel

      3 - Dogwood Therapeutics, Inc. (0001818844) (Issuer)

      10/17/24 4:30:26 PM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DWTX
    Financials

    Live finance-specific insights

    See more
    • Dogwood Therapeutics Announces First Quarter 2025 Financial Results

      - Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Study - - Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b study interim data readout is expected in Q4 2025 - - Cash on hand of $17.5M provides operational runway through Q1 2026 - ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced financial results for the first quarter ended March 31, 2025. "There are no FDA approved treatments to manage the neuropathic pain often resulting from

      5/8/25 9:00:00 AM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

      -Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain ("CINP") Phase 2b Trial - - Halneuron® CINP P2b study interim data readout is expected in Q4 2025 - - Conversion of existing $19.5M in debt to equity, strengthens balance sheet moving forward - - Capital raise provides operational runway through Q1 2026 - ATLANTA, March 31, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced financial results for the fourth quarter and full year ended December 31, 2024. "We have made

      3/31/25 3:45:53 PM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward

      ATLANTA, March 12, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a development-stage biopharmaceutical company focused on advancing first-in-class, non-opioid, treatments for chronic and acute pain, announces that its largest shareholder, CK Life Sciences Int'l., (Holdings), Inc. ("CKLS") has agreed, through its wholly-owned subsidiary, Conjoint Inc. ("Conjoint"), to assign to the Company all outstanding indebtedness under the previously existing $19.5 million Loan Agreement plus accrued interest in exchange for 284.2638 shares of preferred equity of the Company, effective today. "We believe the decision by CKLS to exchange the outst

      3/12/25 8:30:00 AM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DWTX
    SEC Filings

    See more
    • SEC Form EFFECT filed by Dogwood Therapeutics Inc.

      EFFECT - Dogwood Therapeutics, Inc. (0001818844) (Filer)

      6/3/25 12:15:11 AM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by Dogwood Therapeutics Inc.

      S-3 - Dogwood Therapeutics, Inc. (0001818844) (Filer)

      5/23/25 5:25:42 PM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Dogwood Therapeutics Inc.

      10-Q - Dogwood Therapeutics, Inc. (0001818844) (Filer)

      5/9/25 11:28:32 AM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care